
News|Articles|May 1, 2002
Cardiac events: Losartan beats beta blocker in patients with diabetes,HTN, & LVH
Therapy starting with the angiotensin receptor blocker (ARB) losartansignificantly reduced the risk of cardiovascular outcomes and new-onsetdiabetes compared with a beta blocker in older high-risk hypertensive patients,said Björn Dahlöf, MD. The improved outcomes with losartan occurredeven after adjusting for small differences in blood pressure reduction betweenthe two study drugs.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
COVID-19 vaccines could help tumors respond better to immune checkpoint inhibitors
2
Keytruda shows survival edge over Tecentriq, Opdivo in older patients with lung cancer
3
Two studies underscore need for more effective, bladder-sparing therapies in high-risk cancer
4
Gilead’s Single-Tablet HIV Regimen Meets Primary Endpoints
5

















































